Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology.
Daniel N StreblowAlec J HirschJeffrey J StantonAnne D LewisLois ColginAnn J HessellCraig N KreklywichJessica L SmithWilliam F SuttonDavid ChauvinJennifer WooBenjamin N BimberCierra N LeBlancSonia N AcharyaBrian J O'RoakHarjinder SardarMohammad M SajadiZahra R TehraniMark R WalterLuis Martinez-SobridoJames J KobieJ Rachel ReaderKatherine J OlstadTheodore R HobbsErica Ollmann SaphireSharon L SchendelRobert H CarnahanJonas KnochLuis M BrancoJames E CroweKoen K A Van RompayPhillip Lovalentinull Vu TruongDonald N ForthalNancy L HaigwoodPublished in: Nature communications (2023)
Passively administered monoclonal antibodies (mAbs) given before or after viral infection can prevent or blunt disease. Here, we examine the efficacy of aerosol mAb delivery to prevent infection and disease in rhesus macaques inoculated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant via intranasal and intratracheal routes. SARS-CoV-2 human mAbs or a human mAb directed to respiratory syncytial virus (RSV) are nebulized and delivered using positive airflow via facemask to sedated macaques pre- and post-infection. Nebulized human mAbs are detectable in nasal, oropharyngeal, and bronchoalveolar lavage (BAL) samples. SARS-CoV-2 mAb treatment significantly reduces levels of SARS-CoV-2 viral RNA and infectious virus in the upper and lower respiratory tracts relative to controls. Reductions in lung and BAL virus levels correspond to reduced BAL inflammatory cytokines and lung pathology. Aerosolized antibody therapy for SARS-CoV-2 could be effective for reducing viral burden and limiting disease severity.